Patents Assigned to Amgen Inc.
  • Publication number: 20220195022
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 23, 2022
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Publication number: 20220194955
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 23, 2022
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • Patent number: 11364248
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: June 21, 2022
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Kexue Li, Yunxiao Li, Anthony B. Reed, Brian Alan Lanman
  • Publication number: 20220185869
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Applicant: Amgen Inc.
    Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
  • Publication number: 20220187398
    Abstract: Methods of fingerprinting a specific molecule in a composition using nuclear magnetic resonance (NMR) is disclosed. The disclosed NMR methods provide several modifications and improvements over existing NMR techniques. In some embodiments, the methods include applying a cycle of signal processing steps, including applying a radio frequency (RF) pulse, applying a gradient pulse having a pulse length less than or equal to 1000 ?s, and applying a water suppression technique (WET). In some embodiments, the methods further include repeating the cycle for at least 3 times to acquire an enhanced signal of the composition.
    Type: Application
    Filed: March 26, 2020
    Publication date: June 16, 2022
    Applicant: AMGEN INC.
    Inventors: Tsang-Lin HWANG, Mats H. WIKSTROEM
  • Patent number: 11357916
    Abstract: A drug delivery device includes a container for storing a drug, the container having a stopper for expelling the drug; an injection drive comprising an energy source for directly or indirectly acting on the stopper to expel the drug; a sensor for detecting contact between the drug delivery device and a body of a patient; and a user interface (UI) for activating or causing the activation of the injection drive. The device is operative for drawing attention to the UI, if the sensor detects contact between the drug delivery device and the body of the patient, to thereby indicate that the injection drive is ready to be activated, which activation is the next step in the drug administration process.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 14, 2022
    Assignee: AMGEN INC.
    Inventors: Adam B. McCullough, Scott R. Gibson
  • Publication number: 20220177580
    Abstract: Provided herein are methods of modulating Fc gamma Receptor (Fc?R)-mediated cytotoxicity of an antibody composition. In exemplary embodiments, the method comprises (1) increasing or decreasing the amount of terminal ?-galactose at the N-297 glycosylation site of panitumumab, or increasing or decreasing the amount of panitumumab molecules that comprise G1, G1a, G1b and/or G2 galactosylated glycan at the N-297 site, (2) increasing or decreasing the amount of panitumumab molecules that comprise fucosylated glycan at the N-297 site, or increasing or decreasing the amount of panitumumab molecules that comprise afucosylated glycan at the N-297 site, and (3) increasing or decreasing the amount of panitumumab molecules that comprise a high-mannose glycan at the N-297 site.
    Type: Application
    Filed: May 28, 2020
    Publication date: June 9, 2022
    Applicant: AMGEN INC.
    Inventors: SCOTT THOMAS KUHNS, RUPA PADAKI, QINGCHUN ZHANG, WILLIAM S BRETZLAFF
  • Patent number: 11351308
    Abstract: A drug delivery device includes a housing defining a shell, a drug delivery assembly at least partially disposed within the housing, a cap defining an opening and being adapted to at least partially cover an end of the housing, at least one electronic component, a power source which powers the at least one electronic component, and a switch assembly. The drug delivery assembly comprises a guard which engages an inner surface of the housing and is movable between a first position, a second position, and a third position relative to the housing and is adapted to restrict external contact with a cannula. The switch assembly causes the power source to provide power to the at least one electronic component when the cap is removed from the housing, restrict the power source from providing power when the cap is coupled to the housing and the guard is in the first position, and cause the power source to provide power when the cap is coupled to the housing and the guard is in the third position.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 7, 2022
    Assignee: AMGEN INC.
    Inventors: Huaying Yang, Desheng Yin, Ferry Tamtoro, Scott Robert Gibson, Keith P. Kogler, Michael Friedman, Neal Johnston, Adam B. McCullough
  • Patent number: 11352433
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: June 7, 2022
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • Publication number: 20220170074
    Abstract: The present invention relates to methods for detecting and quantifying intact protein-polynucleotide conjugate molecules in various sample matrices. In particular, the methods utilize triplex forming oligonucleotides in combination with protein-specific binding partners to respectively detect the polynucleotide and protein components of the conjugate molecules.
    Type: Application
    Filed: November 29, 2021
    Publication date: June 2, 2022
    Applicant: AMGEN INC.
    Inventors: Mai THAYER, Sara HUMPHREYS
  • Patent number: 11344681
    Abstract: A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: May 31, 2022
    Assignee: AMGEN INC.
    Inventors: Lawrence S. Ring, Dhairya Mehta, Stephanie Toy, Ferry Tamtoro, Alexander Stuart Cairns, Scott R. Gibson
  • Publication number: 20220152154
    Abstract: The present disclosure provides combination therapy with GDF15 molecules. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region, optionally via a linker. In one embodiment, combination therapy comprises administration of a GDF15 molecule with a GLP-1R agonist. In another embodiment, combination therapy comprises administration of a GDF15 molecule with a GIPR antagonist.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 19, 2022
    Applicant: AMGEN INC.
    Inventors: YuMei XIONG, Murielle Marie VENIANT ELLISON
  • Publication number: 20220143181
    Abstract: Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 12, 2022
    Applicant: AMGEN INC.
    Inventors: Stephen Robert BRYCH, Lyanne M. WONG, Jaymille FALLON, Monica Michelle GOSS, Jian Hua GU, Pavan K. GHATTYVENKATAKRISHNA
  • Publication number: 20220146413
    Abstract: Disclosed are methods of determining the suitability of a variable-length spectrophotometer using Patent Blue dye or AMG Blue dye. Also disclosed herein are methods of determining the suitability of a fixed path length spectrophotometer for determining protein concentration of a protein sample. AMG Blue dye may also be used to determine the suitability of fixed path length spectrophotometers.
    Type: Application
    Filed: December 13, 2019
    Publication date: May 12, 2022
    Applicant: Amgen Inc.
    Inventors: Robert John DUFF, Christian GUTIERREZ
  • Publication number: 20220144933
    Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
    Type: Application
    Filed: December 14, 2021
    Publication date: May 12, 2022
    Applicant: AMGEN INC.
    Inventors: Andrew A. WELCHER, Michael J. Boedigheimer, James B. Chung
  • Publication number: 20220144886
    Abstract: The invention provides for the removal of a large fraction of contaminants from protein preparations while maintaining a high level of recovery using tentacle anion exchange matrix chromatography medium. Using the methods of the invention, leached affinity chromatography contaminants can be removed from recombinant protein preparations.
    Type: Application
    Filed: December 17, 2021
    Publication date: May 12, 2022
    Applicant: AMGEN INC.
    Inventors: Samuel Ray TREJO, Robert Perry BRAKE
  • Publication number: 20220136025
    Abstract: The invention provides methods and materials for culturing mammalian cells and harvesting recombinant protein.
    Type: Application
    Filed: November 30, 2021
    Publication date: May 5, 2022
    Applicant: AMGEN INC.
    Inventors: Chetan GOUDAR, Sean COLE, Nicole SABO, Henry LIN, Jonathan LULL, Tharmala THARMALINGAM
  • Publication number: 20220136026
    Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.
    Type: Application
    Filed: December 17, 2021
    Publication date: May 5, 2022
    Applicant: AMGEN INC.
    Inventors: Jian WU, Sean DAVERN, Simina Crina PETROVAN, Michael Charles BRANDENSTEIN, Katherine Rose LINDAHL, Shawn Erik LILLIE
  • Patent number: D951434
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: May 10, 2022
    Assignee: AMGEN INC.
    Inventors: Margaux Frances Boyaval, Sigrid Moeslinger, Lisa Nugent, Brian Stonecipher, Masamichi Udagawa
  • Patent number: D955564
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: June 21, 2022
    Assignee: AMGEN INC.
    Inventors: Margaux Frances Boyaval, Sigrid Moeslinger, Lisa Nugent, Brian Stonecipher, Masamichi Udagawa